NCT03523104Recruiting
Chinese PD-LRRK2 Registry
The Chinese Parkinson's Disease With LRRK2 Variants Registry
Source: ClinicalTrials.gov · Last updated 29 May 2018 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of the Chinese PD-LRRK2 Registry(CPD-LRRK2R) is to develop a database of patients of Parkinson's disease with leucine-rich repeat kinase 2 (LRRK2) gene variants in mainland China.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 1 May 2018
- Start date
- 1 Feb 2017
- Primary completion date
- 1 Feb 2027
- Lead sponsor
- Xiangya Hospital of Central South University
- Diseases
- Parkinson disease
- NCT number
- NCT03523104
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 1 Feb 2017 to the primary completion date, 1 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Who the study is looking for
- Patients diagnosed with PD by the United Kingdom Parkinson's Disease Society Brain Bank clinical diagnostic criteria or other standard criteria; PD patients detected with positive LRRK2 variants
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xiangya Hospital of Central South University Coordinator of this site? Confirm its status | Changsha | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.